Altogether, these results indicate that PKC inhibitors trigger inflammasome activation, IL‐1β release, and pyroptosis in monocytes from FMF patients, while inflammasome is not activated in monocytes from HD. The gene discussed is PRRT2; the disease is Huntington disease.